CAR-T Trial for Myasthenia Gravis in Florida
I cannot identify a specific CAR-T trial for myasthenia gravis at Dignity Health St. Joseph's Hospital in Florida based on the provided evidence. The evidence does not contain information about this particular trial site or its protocols.
What the Evidence Shows About CAR-T for Myasthenia Gravis
The most recent and highest-quality evidence demonstrates that anti-CD19 and anti-BCMA CAR-T cell therapy is safe and highly effective for refractory generalized myasthenia gravis, with 82-100% of patients achieving minimal manifestations or drug-free remission. 1, 2, 3
Key Clinical Trial Results
The strongest evidence comes from a 2025 phase 1 trial of anti-BCMA/CD19 bispecific CAR-T cells in 18 patients with refractory generalized myasthenia gravis 1:
Inclusion Criteria:
- Refractory generalized myasthenia gravis
- MG-ADL score ≥6 points
- QMG score ≥8 points
- Failed conventional immunosuppression
Treatment Protocol:
- Autologous anti-BCMA/CD19 bispecific CAR-T cells
- Dose escalation: 1.0 × 10⁶, 3.0 × 10⁶, or 5.0 × 10⁶ CAR-T cells per kg
- Single infusion without prior lymphodepletion in some protocols 3
Outcomes at 180 Days:
- MG-ADL score improved by -8.6 points (95% CI -10.2 to -7.0)
- QMG score improved by -15.4 points (95% CI -17.6 to -13.2)
- 82% achieved minimal manifestations status
- 88% discontinued glucocorticoids
- 100% stopped non-steroidal immunosuppressants
- 47% achieved anti-AChR antibody negative seroconversion
Safety Profile
The safety profile in myasthenia gravis is substantially more favorable than in oncology applications 1, 2, 4:
- Cytokine Release Syndrome (CRS): Only grade 1 in 39% of patients (no grade 2-4 CRS observed) 1
- ICANS: No immune effector cell-associated neurotoxicity syndrome reported 1
- Hematologic toxicities: Grade 3+ events included transient leukopenia, neutropenia, anemia, and thrombocytopenia—all manageable 1
- No dose-limiting toxicities or treatment-related deaths
This contrasts sharply with oncology applications where CRS rates range from 37-93% with higher grade severity 5.
Mechanism and Durability
CAR-T cells induce profound B-cell depletion with sustained clinical benefits extending beyond B-cell reconstitution 2, 3:
- Peak CAR-T expansion occurs 8-22 days post-infusion 6
- B-cell depletion is profound and sustained
- When B-cells reconstitute, they show naïve predominance with diminished AChR specificity 7
- Clinical remission persists for at least 19 months despite B-cell recovery 2
- Responses maintained even with detectable anti-AChR antibodies 2
Comparison to Other Therapies
Unlike rituximab and other B-cell depleting agents that require repeated administration and rarely induce durable remission, CAR-T therapy offers potential for sustained drug-free remission after a single infusion 2, 4. Some patients with disease refractory to rituximab showed ABC expansion and FCRL5 up-regulation, suggesting CAR-T may target different B-cell populations 7.
Current Trial Landscape
Seven registered trials enrolling over 260 patients are expected to conclude between 2026-2029 6. These will provide more definitive data on:
- Long-term efficacy and durability
- Optimal patient selection criteria
- Standardized dosing protocols
- Organ-specific assessments
Clinical Implications
For patients with refractory generalized myasthenia gravis who have failed conventional immunosuppression and biologics, CAR-T cell therapy represents a potentially transformative option 4, 6. The therapy appears capable of inducing an "immune reset" that shifts immunity toward a healthy state 4.
Important caveats:
- Current evidence limited to small case series and phase 1 trials
- Long-term safety beyond 19 months not yet established
- Optimal target (CD19 vs BCMA vs bispecific) remains unclear
- Patient selection criteria need refinement
- Cost and logistical complexity remain significant barriers
Monitoring Requirements
Based on autoimmune disease CAR-T guidelines 8, 9:
- Multidisciplinary team evaluation is mandatory
- Early treatment of CRS recommended even at grade 1 (consider tocilizumab 8 mg/kg IV) 8
- Comprehensive baseline neurological assessment required 10
- Distinguish disease flare from CAR-T toxicity through careful monitoring 8
- B-cell subset monitoring at leukapheresis, B-cell reappearance, and months 1,3,6,12,24 8